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Abstract
Background: Infraorbital nerve constriction (IoNC) is an experimental model of trigeminal neuropathy. We investigated if
IoNC is accompanied by dural extravasation and if botulinum toxin type A (BoNT/A) can reduce pain and dural extravasation
in this model.
Methodology/Principal Findings: Rats which developed mechanical allodynia 14 days after the IoNC were injected with
BoNT/A (3.5 U/kg) into vibrissal pad. Allodynia was tested by von Frey filaments and dural extravasation was measured as
colorimetric absorbance of Evans blue - plasma protein complexes. Presence of dural extravasation was also examined in
orofacial formalin-induced pain. Unilateral IoNC, as well as formalin injection, produced bilateral dural extravasation. Single
unilateral BoNT/A injection bilaterally reduced IoNC induced dural extravasation, as well as allodynia (lasting more than 2
weeks). Similarly, BoNT/A reduced formalin-induced pain and dural extravasation. Effects of BoNT/A on pain and dural
extravasation in IoNC model were dependent on axonal transport through sensory neurons, as evidenced by colchicine
injections (5 mM, 2 ml) into the trigeminal ganglion completely preventing BoNT/A effects.
Conclusions/Significance: Two different types of pain, IoNC and formalin, are accompanied by dural extravasation. The
lasting effect of a unilateral injection of BoNT/A in experimental animals suggests that BoNT/A might have a long-term
beneficial effect in craniofacial pain associated with dural neurogenic inflammation. Bilateral effects of BoNT/A and
dependence on retrograde axonal transport suggest a central site of its action.
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Introduction
In animals, long-lasting antinociception of peripherally applied
botulinum toxin type A (BoNT/A) was reported in inflammatory
pain induced by formalin [1], carrageenan and capsaicin [2], [3],
peripheral neuropathic pain [4]–[8], postsurgical pain [9],
experimental cystitis [10] and prostatitis [11]. Bilateral effect of
unilaterally applied BoNT/A was demonstrated in different
models [12]–[14]. Retrograde transport in sensory neurons and
central site of BoNT/A action were suggested [12], [13] to explain
this bilateral effect.
Infraorbital nerve constriction injury (IoNC) accompanied by
hyperalgesia and allodynia is used as a model of trigeminal
neuropathy in rats [15]. Standard antimigraine drugs, like 5-
HT1B/1D receptor agonists and some antiepileptics reduce
mechanical allodynia and hyperalgesia after the IoNC [16],
[17]. BoNT/A pretreatment prevented the development of IoNC-
induced trigeminal neuropathy [7], [8].
In the present study we found that: (1.) two types of pain in
trigeminal region, IoNC and formalin injection, are, apart from
mechanical allodynia, accompanied by dural protein extravasa-
tion; (2.) BoNT/A, besides bilateral reduction of pain, also
bilaterally reduces dural extravasation in IoNC model; (3.) BoNT/
A effects on pain and dural neurogenic inflammation are
dependent on axonal transport in trigeminal sensory neurons.
Materials and Methods
Animals and Ethics statement
A total number of 200 male Wistar rats (300–350 g), bread in
our animal facility (University of Zagreb School of Medicine,
Croatia), were included in the study. Animals were kept under a
constant 12 h/12 h light/dark cycle with unlimited access to food
and water. The experiments were conducted according to the
National Institute of Health Guide for the Care and Use of
Laboratory Animals (Publication No. 85-23, revised 1996) and
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School of Medicine (permit No. 07-76/2005-43).
Drugs
The following drugs were used: botulinum toxin type A
(BotoxH, Allergan, Inc., Irvine, CA, USA); chloral hydrate,
colchicine and formamide (Sigma, St. Louis, MO, USA); Evans
blue (Merck KGaA, Darmstadt, Germany); formalin (Kemika,
Zagreb, Croatia). Colchicine was reconstituted in 0.9% saline to
obtain the 5 mM concentration. Each vial of BotoxH contains
100 U of purified Clostridium botulinum type A neurotoxin
complex. One unit of BotoxH contains approximately 48 pg of
whole molecular complex of BoNT/A, with molecular weight of
900 kDa. In order to obtain the dose needed, BoNT/A was
reconstituted in adequate volume of 0.9% saline. Evans blue was
reconstituted in 0.9% saline to obtain the required dose (40 mg/
kg). Formalin was diluted to 2.5% concentration with saline.
BoNT/A was injected subcutaneously (s.c.) in a volume of 20 ml
with a 27 K gauge syringe into the ipsilateral or contralateral
vibrissal pad of conscious, restrained rats. Control animals were
injected with saline. BoNT/A dose of 3.5 U/kg was chosen on the
basis of previous experiments [1], [13], [18]. Colchicine (2 ml) was
injected into the trigeminal ganglion (i.g.) of anesthetized rat as
described by Neubert et al. [19]. Hamilton syringe needle
(Hamilton Microliter #701, Hamilton, Bonaduz, Switzerland)
was inserted through the skin into the infraorbital foramen, and
advanced through the infraorbital canal and foramen rotundum
into the trigeminal ganglion. Formalin was injected subcutane-
ously (s.c.) into the vibrissal pad of conscious, restrained rats in a
volume of 50 ml with a 27 K gauge syringe.
Surgery
Animals were anesthetized by a single intraperitoneal injection of
chloral hydrate (300 mg/kg). Chronic constriction injury to the left
infraorbital nerve was performed as described previously [15]. The
skin on the left side of the forehead and nose of the rat was shaved.
1 ml of saline was injected into the medial portion of the orbit to
elevate the eye in order to gain a better access to the infraorbital
nerve. A mid-line scalp incision was made, exposing skull and nasal
bone. Electrocauterization was used to prevent bleeding. The
intraorbital part of infraorbital nerve was exposed using a modified
surgical procedure [20]. Medial edge of the orbit was dissected free
and orbital contents were gently elevated using small cotton balls.
The infraorbital nerve was dissected and two silk ligatures (5-0) were
placed around the nerve spaced 2 mm apart. The ligatures reduced
the diameter of the nerve by just a noticeable amount and they did
not interrupt the epineural circulation, as previously described [21].
Orbital content was then gently moved back to orbit. Skin and
underlying fascia were sutured in layers with nylon sutures (4-0).
Sham operation was performed by exposing infraorbital nerve
without placing silk ligatures.
Mechanical allodynia testing
Von Frey monofilaments (Stoelting Co., Wood Dale, IL, USA)
were used for mechanical stimulation. The filaments produced a
bendingforceof0.16,0.4, 0.6, 1,2,4,6,8,10and15 g.Testing was
performed as previously described in detail by Kayser et al. [17].
The rats were placed in a small transparent plastic cage for ten
minutes to accommodate to the experimental environment until
they assumed their normal sniffing/no locomotion position. For
each session, series of von Frey filaments were applied on the tested
side of the face in ascending order, starting at 0.16 g, until a defined
behavioral response was elicited. Each time, the measurement
started on the side contralateral to IoNC injury. A positive reaction
to the stimulation within the IoN territory, at the center of the
vibrissal pad area, consisted of a rapid withdrawal of the head and/
or attack/escape reaction [15]. If no response was observed, we
assigned 15 g as the withdrawal threshold, since the pressure
exerted by thickest (15 g) filament was enough to push the head of
sham-operated rats. Measurements were performed three times for
each filament on both sides of the face in 10 min intervals. Baseline
measurements were performed one day prior to the IoNC injury.
Pain sensitivity wasretested fourteen daysfollowingthe IoNC injury
(day 0). Time between the surgery and testing was chosen based on
the time required for full development of mechanical sensitivity in
IoNC model [15], [17] and aimed to exclude the possible influence
of postsurgical hyperalgesia on pain testing [9]. Only animals which
developed bilateral mechanical allodynia (we defined it as
responsiveness to 0.16–2 g on both sides) were included in the
further study (approximately 70% of the IoNC operated animals).
Dural extravasation
Evans blue (dye which complexes with plasma proteins) technique
is routinely used to investigate the effects of nociceptive afferents on
vascular function [3], [22]. Animals were injected with 1 ml Evans
blue solution (40 mg/kg) into the tail vein. After stimulation of the
vibrissal pad area with von Frey filament (2 g) for a period of
10 minutes, animals were deeply anesthetized by chloral hydrate
(300 mg/kg, i.p), the thorax was opened and the right atrium incised
for drainage. Saline (500 ml) was perfused via left ventricle at a
constant rate. The brain was carefully removed and the cranial
cavity rinsed with saline to remove residual blood and cerebrospinal
fluidpriortodissectionofthe dura.Theduracoveringsupratentorial
region of the brain, primarily innervated by trigeminal nerve [23],
was harvested from left and right side separately. To assess bilateral
dural extravasation, dural tissue from 4 animals was pooled in one
sample (left and right side separately) and weighted. Average weight
was 10–18 mg. Collected tissue was incubated in 2 ml of formamide
at 37uC for 48 h. Colorimetric absorbance measurements of Evans
blue formamide extracts were carried out with a spectrophotometer
(Iskra, Ljubljana, Slovenia) at 620 nm.
Experimental design
Time course of bilateral mechanical allodynia. Animals
which developed mechanical allodynia on day 14 after IoNC were
divided in4 groups (5–8 animals):1. Shamoperated; 2. IoNC+Saline;
3. IoNC+BoNT/A (ipsi.) (BoNT/A injected ipsilateral to the IoNC
injury); 4. IoNC+BoNT/A (contra.) (BoNT/A injected contralateral
to the IoNC injury). Measurements of mechanical sensitivity were
further repeated on day 3, 6, 20 and 30 following BoNT/A single
injection (day 0).
Bilateral assessment of dural neurogenic inflamma-
tion. Plasma dural extravasation was investigated in additional
4 groups of animals (20 animals per group): 1. Sham operated; 2.
IoNC+Saline;3.IoNC+BoNT/A(ipsi.);4.IoNC+BoNT/A(contra.)
Fourteen days after the IoNC injury, neuropathic animals were
selected similarly to that described above, and injected with BoNT/
A or saline.Threedaysafter the injection,allodyniawasretestedand
Evans blue technique was employed to test dural plasma protein
extravasation.
Characterization of axonal transport of BoNT/A. To test
the role of axonal transport of BoNT/A in sensory neurons for its
effects on bilateral neuropathic pain and dural extravasation, an
axonal transport blocker colchicine was injected into the
trigeminal ganglion.
After 24 hrs, animals pre-treated with colchicine were injected
s.c. into the vibrissal pad with BoNT/A or saline into the side
ipsilateral to the IoNC injury and colchicine injection.
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(i.g.)+saline (s.c.): IoNC+saline (i.g.)+BoNT/A (s.c.); IoNC+colchi-
cine (i.g.)+saline (s.c. ); IoNC+colchicine (i.g)+BoNT/A (s.c.).
Experimental procedure for bilateral measurements of mechan-
ical allodynia and dural extravasation was similar to that described
above, except that the dural samples were not divided into left and
right sides and were not pooled, because we observed no
significant difference between dural extravasation on opposite
sides.
Orofacial formalin test. Animals pretreated with saline or
BoNT/A (3.5 U/kg into the vibrissal pad) 3 days prior to testing
were injected with Evans blue. Immediately following Evans Blue
administration the animals were injected unilaterally with 2.5%
formalin (50 ml) into the BoNT/A treated vibrissal pad and placed
in transparent cages for 45 min of observation. Behavioral testing
was performed as previously described [18], [24]. In brief, facial
rubbing time (in seconds) was measured in 3 minute intervals for a
period of 45 min.
Following behavioral testing, animals were immediately anes-
thetized and perfused with saline. Left and right sides of dural
tissue were excised and pooled from two animals.
Animals were divided in 3 groups (8 animals per group): 1.
control: saline (s.c.); 2. saline (s.c.)+formalin (s.c.); 3. BoNT/A
(s.c.)+formalin (s.c.).
Statistical analysis
The results were presented as mean 6 S.E.M and analyzed by
ANOVA followed by the Newman-Keuls post hoc test for
between-group differences. In the time-course experiment AN-
OVA was employed for repeated measurements followed by
Tukey’s test. P,0.05 was considered significant.
Results
Effects of BoNT/A on allodynia induced by IoNC injury
BoNT/A (3.5 U/kg) injected s.c. into the vibrissal pad
(ipsilaterally to the nerve injury) of animals which developed
Figure 1. Botulinum toxin A (3.5 U/kg) decreases mechanical allodynia induced by IoNC- injury in rats. BoNT/A was injected into the
vibrissal pad ipsilaterally (A and B) or contralaterally (C and D) to the side of the nerve injury. Measurements were performed on the ipsilateral (A and
C) and contralateral (B and D) side to the nerve injury. Legend: & – sham-operated control; ¤ - saline-injected IoNC operated animals when
measured on the ipsilateral side;N - saline-injected IoNC operated animals when measured on the contralateral side; * - BoNT/A-injected IoNC
operated animals when measured on the ipsilateral side; m – BoNT/A-injected IoNC operated animals when measured on the contralateral side. Mean
6 S.E.M; n=5–8 (n- indicates the number of animals per group). *P,0.01 - BoNT/A-injected compared to saline-injected animals;
+P,0.001 - BoNT/A-
injected or saline-injected animals compared to sham-operated control.
doi:10.1371/journal.pone.0029803.g001
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mechanical allodynia on that side, as well as on the
contralateral side (Figure 1A and 1B). When BoNT/A was
injected contralaterally to the nerve injury, it still reduced
mechanical allodynia on both sides of the face (Figure 1C and
1D). The effect on both sides was evident on our first
measurement 3 days post BoNT/A injection, and persisted for
at least 17 more days. On day 44 following the IoNC injury (day
30 post-BoNT/A application), mechanical allodynia started to
disappear (Figure 1 A, B, C, D). To exclude the possibility of
BoNT/A passive diffusion away from the site of injection,
methylene blue (20 ml) was injected into the vibrissal pad. The
colour only resided near the place of injection and did not
spread away from the site of injection (data not shown).
Moreover, animals injected into the vibrissal pad with 3.5 U/kg
of BoNT/A or even higher doses (15 U/kg) did not exhibit
impaired rotarod performance which excludes possible systemic
effect (results not shown).
Effects of BoNT/A on dural extravasation after IoNC injury
In the IoNC operated saline treated rats with bilateral
mechanical allodynia, dural extravasation (measured as ng of
Evans blue per mg of dural tissue) was measured three days after
BoNT/A injection into the vibrissal pad, i.e. 17-days post-IoNC
injury. BoNT/A (3.5 U/kg) abolished bilateral dural extrava-
sation in the IoNC injured rats (Figure 2). Botulinum toxin
exerted the effect on dural extravasation when injected both
ipsilaterally or contralaterally to the site of nerve injury
(Figure 2).
Effect of BoNT/A on mechanical allodynia and dural
extravasation after IoNC injury is axonal transport
dependent
Mechanical bilateral allodynia and dural extravasation were
significantly reduced 2 and 3 days following the BoNT/A injection
into the vibrissal pad. When axonal transport blocker colchicine
was injected ipsilateral to BoNT/A injection into the trigeminal
ganglion, BoNT/A failed to reduce bilateral mechanical allodynia
(Figure 3) and dural neurogenic extravasation (Figure 4). Colchi-
cine itself did not alter either mechanical allodynia (Figure 3) or
dural neurogenic inflammation induced by IoNC (Figure 4),
although it was previously shown that it affects thermal
hyperalgesia in experimental animals [25].
Orofacial formalin test
BoNT/A (3.5 U/kg) reduced formalin-induced painful behav-
iour, measured as time of facial rubbing, during phase II of
formalin test (results not shown), which is in line with our previous
findings [18].
Formalin-induced orofacial pain also resulted in bilateral dural
extravasation (measured as amount of Evans-blue extravasated
dye), similarly to IoNC. Unilaterally applied BoNT/A reduced
dural extravasation on both sides, as well (Figure 5).
Discussion
Trigeminal pain-evoked dural protein extravasation
Dural neurogenic inflammation is a phenomenon which is only
superficially investigated. There is sparse evidence for its existence
Figure 2. Botulinum toxin A (3.5 U/kg) decreases dural extravasation in IoNC injured rats. BoNT/A was injected into the vibrissal pad 14
days after infraorbital constriction ipsilaterally or contralaterally to the side of nerve injury. Absorbances of Evans blue extracted from dural tissue after
incubation in formamide were measured. Each sample consists of combined dural tissue of 4 animals. Corresponding amounts of Evans blue were
calculated from calibration curve, and divided by the wet mass of corresponding dural samples. Legend: Sham-operated animals; IoNC+saline – saline
injected animals after IoNC injury; IoNC+BoNT/A ( ipsi.) – BoNT/A injected ipsilaterally in IoNC operated animals; IoNC+BoNT/A (contra.) – BoNT/A injected
contralaterally in IoNC operated animals. Mean 6 S.E.M., n=5 (n-indicates the number of samples per group). *P,0.01 (Newman Keuls post-hoc).
doi:10.1371/journal.pone.0029803.g002
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pretreatment. Animals were injected into the trigeminal ganglion with colchicine 24 hrs prior to s.c. BoNT/A or saline injection into the vibrissal pad
(both injections given into the ipsilateral side to the IoN injury). Animals were divided in 5 groups: Sham operated; IoNC+saline (i.g.)+saline (s.c.);
IoNC+saline (i.g.)+BoNT/A; IoNC+colchicine (i.g.)+saline (s.c.); IoNC+colchicine (i.g.)+BoNT/A (s.c.). Measurements were performed on the ipsilateral and
contralateralsidetothenerveinjury.Shamoperatedvalues(around12.560.5 g)werenot shown.Mean6S.E.M.,n=6(n-indicatesthenumberofanimals
per group). *P,0.01 compared to IoNC+saline (i.g.)+saline (s.c.); IoNC+colchicine (i.g.)+saline (s.c.); IoNC+colchicine (i.g.)+BoNT/A (s.c.) (Tukey’s test).
doi:10.1371/journal.pone.0029803.g003
Figure 4. BoNT/A (3.5 U/kg) decreases dural extravasation in IoNC-injured rats which is prevented by intraganglionic colchicine.
Animals were injected into the trigeminal ganglion with colchicine 24 hrs prior to s.c. BoNT/A or saline injection into the vibrissal pad (both injections
given into the ipsilateral side to the IoN injury). Absorbances of Evans blue extracted from dural tissue after incubation in formamide were measured.
Legend: i.g. - intraganglionic; s.c. – subcutaneous injection. Data are represented as mean 6 S.E.M., n=6 (n-indicates the number of samples per
group). *P,0.01 (Newman Keuls post-hoc).
doi:10.1371/journal.pone.0029803.g004
Botulinum Toxin Lowers Pain and Dural Inflammation
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29803in humans [26] and it was primarily investigated in relation to
migraine in an animanl model [27]–[31]. According to trigemi-
novascular theory, migraine is associated with activation of
trigeminal nerve afferents which innervate dura, leading to release
of neuropeptides like calcitonin gene related peptide (CGRP) and
substance P (SP) [32]. It can be evoked by electrical stimulation of
trigeminal ganglion and systemic chemical or immunological
stimulation [33]. Classical antimigraine agents (like ergot alkaloids,
triptans), decrease dural plasma protein extravasation after
electrical stimulation of trigeminal ganglion [27]–[31].
As a new finding of this study we have shown that dural
extravasation can be induced by two different types of trigeminal
pain (neuropathic and inflammatory).
Nerves which innervate the dura (middle meningeal nerve) and
area innervated by infraorbital nerve (affected by IoNC and
formalin) belong to the maxillary trigeminal branch, but they are
distinct and physically separated [23]. Possible explanations for
dural extravasation after IoNC and formalin could be: (1)
interactions between neurons innervating the injured infraorbital
nerve area with adjacent neurons in trigeminal ganglion
innervating dural vessels, and/or (2) central cross-excitation inside
spinal trigeminal nucleus in the brainstem. Mutual activation
between the adjacent neurons of the same ganglion has been
described in trigeminal and dorsal root ganglia [34], [35]. Based
on the animal model of chemical stimulation of dura, it was
proposed that the coexistence of dural extravasation and allodynia
is modulated by excitation of nociceptive neurons in trigeminal
nucleus caudalis, a convergent point of sensory inputs from dura
and facial skin [36], [37].
Allodynia and dural extravasation on the side contralateral to
nerve injury might be associated with spreading of excitation to
contralateral nuclei, via unknown neural pathways. It is shown
that unilateral electrical stimulation of trigeminal ganglion results
in bilateral decrease of neuropeptides, suggesting the activation of
contralateral trigeminal pathway [38]. Using unilateral injection of
retrograde tracers, Jacquin et al. [39] found that some primary
trigeminal afferents cross the midline and terminate in contralat-
eral dorsal horn, which might explain our observation.
Bilateral effect of BoNT/A on allodynia and dural
extravasation
It was recently demonstrated that BoNT/A counteracts the
development of unilateral neuropathy which follows IoNC [7], [8].
Previously mentioned studies used a different experimental setup:
contralateral side was sham-operated, and BoNT/A was admin-
istered before the development of neuropathy. In our present
study, sham operation was done on a separate group of animals
and, additionally, we administered BoNT/A following the full
development of neuropathic pain. Using this approach, we have
observed BoNT/A bilateral effects on allodynia, lasting over a
period of one month. This effect was seen even when BoNT/A
was applied to the uninjured side (Figure 1).
Bilateral pain reduction after unilateral peripheral BoNT/A
injection has recently been demonstrated in models of paclitaxel-
induced polyneuropathy [14], diabetic neuropathy [13] and acidic
saline-induced mechanical hyperalgesia in rats [12]. Bach-Rojecky
and Lackovic ´ [12] demonstrated that BoNT/A effects are CNS
mediated and dependent on axonal transport. Apart from bilateral
pain reduction in IoNC, effect of BoNT/A was bilateral in both
IoNC and formalin-evoked dural extravasation. Contralateral
effect of BoNT/A might ensue via contralaterally terminating
afferent sensory fibers [39] or by transcytosis within central
neurons, as suggested by some authors [7], [40].
Figure 5. BoNT/A (3.5 U/kg) decreases orofacial formalin-induced dural extravasation. Dural extravasation was induced by formalin
injection into the vibrissal pad (2.5% formalin, 50 ml). Ipsilateral vibrissal pad was injected with saline of BoNT/A 3 days prior to formalin injection.
Amount of Evans blue extracted from dural tissue after incubation in formamide was measured. Ipsi: dural tissue ipsilateral to injections; Cont: dural
tissue contralateral to injections. Control: saline -injected animals; saline+formalin: animals injected with saline and formalin; BoNT/A+formalin:
animals injected with BoNT/A and formalin. Data are represented as mean 6SEM. n=4 (n –number of samples/group), *,- P,0.05 compared to
control; + -P ,0.05 compared to saline+formalin (Newman-Keuls post hoc).
doi:10.1371/journal.pone.0029803.g005
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extravasation is unclear. It might be connected with BoNT/A
effects on CGRP/SP release. In several in vitro studies on cultured
trigeminal ganglion neurons or brainstem slices, BoNT/A reduced
stimulated CGRP release [41]–[43]. In addition, BoNT/A
reduces Substance P release in rabbit iris sphincter [44]. Since
an increased level of CGRP might be important in vasodilatation
and transmission of pain in migraine, some authors propose that
BoNT/A effectiveness in migraine is associated with reduced
CGRP release from trigeminal neurons [41], [45], [46].
Axonal transport of BoNT/A in sensory trigeminal
neurons
Axonal transport of BoNT/A has recently been demonstrated
in motoneurons [40] and sensory neurons [18]. Truncated SNAP-
25 was immunohistochemically demonstrated in medullary dorsal
horn after BoNT/A (3.5 U/kg) injection into the rat vibrissal pad
[18]. Apparently, BoNT/A enters peripheral trigeminal nerve
endings and is axonally transported through the trigeminal
ganglion to the spinal trigeminal nucleus.
Since axonal transport to CNS was shown to be necessary for
antinociceptive activity of BoNT/A [12], [18], we hypothesized
that bilateral reduction of allodynia and dural extravasation are
dependent on BoNT/A axonal transport in sensory neurons. In
line with this hypothesis is our present finding that BoNT/A
effectively reduced pain and dural extravasation even when
applied to uninjured side of neuropathic animals.
Colchicine, prevented both effects of peripherally applied
BoNT/A, most probably by blocking axonal transport of
BoNT/A in trigeminal sensory neurons. These results additionally
exclude bilateral effect due to possible peripheral spreading to
uninjected side of the face. Importantly, this experiment also
shows that trigeminal sensory system is the primary site of BoNT/
A action and excludes possible involvement of extracranial
autonomous nerves.
Conclusion
Present results demonstrate for the first time that bilateral dural
neurogenic inflammation can be evoked by experimental pain in
trigeminal region. Both pain and dural neurogenic inflammation
can be prevented by single BoNT/A peripheral injection,
provided by axonal transport in sensory neurons. Although the
central site of BoNT/A action seems the only logical explanation,
the precise mechanism requires further elucidation. The possibility
that dural extravasation occurs in other types of extracranial pain
and its importance for trigeminal pain pathophysiology should be
further investigated.
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